中国癌症杂志 ›› 2024, Vol. 34 ›› Issue (3): 250-258.doi: 10.19401/j.cnki.1007-3639.2024.03.002
收稿日期:
2024-02-20
修回日期:
2024-03-11
出版日期:
2024-03-30
发布日期:
2024-04-08
通信作者:
汪学非(ORCID: 0000-0002-2645-0953),博士,主任医师,复旦大学附属中山医院胃肠外科主任。
作者简介:
汪学非,主任医师、博士研究生导师,复旦大学附属中山医院普通外科副主任、胃肠外科主任,并同时担任复旦大学附属中山医院厦门医院普通外科执行主任。复旦大学附属中山医院优秀骨干人才,上海市杰出青年医学人才,上海市浦江人才计划获得者。美国哈佛医学院Brigham and Women’s Hospital/Dana-Farber Cancer Institute访问学者(2016—2017年)。上海市医学会普外科专科分会委员兼秘书长,上海市医学会普外科专科分会胃肠外科学组副组长,上海市抗癌协会第一届胃癌专业委员会副主任委员,上海市抗癌协会第三届胃肠道肿瘤专业委员会常务委员,第二届中国研究型医院学会消化道肿瘤专业委员会委员,中国抗癌协会第六届胃癌专业委员会外科学组、微创外科学组和ERAS学组委员,中国医师协会外科医师分会肿瘤外科专家工作组、上消化道外科专家工作组委员,中国医疗保健国际交流促进会胃肠外科学会副主任委员。常规开展普外科常见三、四级腹腔镜手术治疗,尤其擅长胃肠道肿瘤的规范化手术、微创外科和多学科团队综合治疗。在上海、厦门两地年门急诊量3 000余人次,年手术量近600台。长期从事胃癌的临床和基础研究,尤其是进展期胃癌围手术期的综合治疗。作为项目负责人已牵头完成两项临床研究:① 阿帕替尼联合SOX方案用于局部进展期胃腺癌及食管胃连接部腺癌新辅助治疗的Ⅱ期临床研究,相关研究成果已发表在BMC Medicine杂志上;② 放化疗联合PD-1抗体卡瑞利珠单抗在局部进展期胃腺癌及食管胃连接部腺癌新辅助治疗中疗效及安全性的单臂、单中心、前瞻性临床研究,相关研究成果也已发表在Nature Communications期刊上。此外,作为项目负责人还牵头在研三项临床研究:① 合并淋巴结转移与淋巴血管浸润的进展期胃癌根治术后辅助放化疗和化疗疗效与安全性的RCT研究;② HIPEC联合AS方案用于胃或食管胃连接部腺癌腹膜种植转移围手术期疗效与安全性的单中心、前瞻性临床研究;③ 经导管动脉栓塞化疗联合替雷利珠单抗在局部进展期胃腺癌新辅助治疗中安全性和有效性的单臂、单中心、前瞻性临床研究。同时围绕综合治疗效果的预测评估开展了相关的基础研究,研究成果已发表在Cell Reports Medicine、International Journal of Surgery、British Journal of Cancer等期刊上。与复旦大学上海医学院、复旦大学生命科学学院、复旦大学生物医学研究院、中科院系统生物学重点实验室、上海交通大学系统生物医学研究院、美国哈佛医学院Brigham and Women’s Hospital/Dana-Farber Cancer Institute等建立了非常良好的研究合作平台,围绕胃癌分子病理学诊断与预后模型、胃癌转移和复发的分子机制以及血清学诊断等领域开展了一系列基础研究,相关研究成果已在Cancer Research、Gastroenterology、Gut、Molecular Cancer Research等期刊上发基金资助:
WANG Xuefei(), ZHOU Peng, TANG Zhaoqing
Received:
2024-02-20
Revised:
2024-03-11
Published:
2024-03-30
Online:
2024-04-08
Contact:
WANG Xuefei
文章分享
摘要:
胃癌严重威胁人类健康,尽管近年来化疗、靶向治疗和免疫治疗等新型药物研发不断取得突破,但根治性手术始终是胃癌诊疗的核心。随着标准胃癌根治手术的成型,以腹腔镜技术为代表的微创外科治疗技术的进步,进展期胃癌围手术期综合治疗模式的确定,以及胃癌精准外科理念的形成和初步实践,胃癌手术治疗取得了巨大进步。个体化和精准化胃癌外科治疗理念深入人心。安全、有效、精准、微创始终是胃癌外科医师需牢牢把握的学科发展的内在规律。为帮助年轻医师更好的成长,本文总结胃癌诊疗的最新进展,并对未来的发展趋势进行展望。
中图分类号:
汪学非, 周鹏, 唐兆庆. 胃癌外科治疗的新进展及发展趋势[J]. 中国癌症杂志, 2024, 34(3): 250-258.
WANG Xuefei, ZHOU Peng, TANG Zhaoqing. New progress and development trend of surgical treatment for gastric cancer[J]. China Oncology, 2024, 34(3): 250-258.
表1
中、日、韩学者开展的应用微创外科技术的研究"
Surgical scope | Case characteristic | Study name | Study design | Major investigator | Case N | Primary study endpoint |
---|---|---|---|---|---|---|
Distal stomach | Early gastric cancer | KLASS-01[ | Stage Ⅲ RCT | Woo Jin Hyung (Yonsei University) | 1 416 | 5-year disease-free survival rate |
JCOG0912[ | Stage Ⅲ RCT | Hitoshi Katai (National Cancer CenterJapan) | 921 | Recurrence-free survival | ||
Advanced gastric carcinoma | CLASS-01[ | Stage Ⅲ RCT | LI Guoxin (Nanfang Hospital, Southern Medical University) | 1 039 | 3-year recurrence-free survival rate | |
Whole stomach | Early gastric cancer | CLASS-02[ | Stage Ⅲ RCT | SUN Yihong (Zhongshan University, Fudan University) | 227 | Postoperative complication rate and mortality |
KLASS-03[ | Stage Ⅱ single-arm study | Gyu Seok Cho (Soonchunhyang University) | 160 | Postoperative complication rate and mortality | ||
JCOG1401[ | Stage Ⅱ single-arm study | Hitoshi Katai (National Cancer CenterJapan) | 195 | Postoperative complication rate and mortality | ||
Advanced gastric carcinoma | CLASS-07 | Stage Ⅲ RCT | SUN Yihong (Zhongshan University, Fudan University) | 1 316 | OS | |
KLASS-06 | Stage Ⅲ RCT | Woo Jin Hyung (Yonsei University) | 772 | 3-year recurrence-free survival rate |
[1] | ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46: 221-231. |
[2] |
YANG W J, ZHAO H P, YU Y, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer[J]. World J Gastroenterol, 2023, 29(16): 2452-2468.
doi: 10.3748/wjg.v29.i16.2452 |
[3] |
SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396 (10251): 635-648.
doi: S0140-6736(20)31288-5 pmid: 32861308 |
[4] |
SATO H, NOSHIRO H. Report about the present condition of Billroth’s stomach specimens[J]. Gastric Cancer, 2019, 22(6): 1310-1311.
doi: 10.1007/s10120-019-00987-z |
[5] | GHOSSAIN A, GHOSSAIN M A. History of mastectomy before and after Halsted[J]. J Med Liban, 2009, 57(2): 65-71. |
[6] | 日本胃癌学会. 胃癌处理规约[M]. 10版. 东京: 金原出版株式会社, 1979. |
Japanese Gastric Cancer Association. Gastric cancer management protocol[M]. 10 edition. Tokyo: Kanehara Publishing Co., LTD, 1979. | |
[7] |
CUSCHIERI A, FAYERS P, FIELDING J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group[J]. Lancet, 1996, 347(9007): 995-999.
doi: 10.1016/s0140-6736(96)90144-0 pmid: 8606613 |
[8] |
BONENKAMP J J, HERMANS J, SASAKO M, et al. Extended lymph-node dissection for gastric cancer[J]. N Engl J Med, 1999, 340(12): 908-914.
doi: 10.1056/NEJM199903253401202 |
[9] |
SONGUN I, PUTTER H, KRANENBARG E M, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5): 439-449.
doi: 10.1016/S1470-2045(10)70070-X pmid: 20409751 |
[10] |
SASAKO M, SANO T, YAMAMOTO S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J]. N Engl J Med, 2008, 359(5): 453-462.
doi: 10.1056/NEJMoa0707035 |
[11] |
TSUBURAYA A, MIZUSAWA J, TANAKA Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J]. Br J Surg, 2014, 101(6): 653-660.
doi: 10.1002/bjs.9484 pmid: 24668391 |
[12] |
KUROKAWA Y, TAKEUCHI H, DOKI Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study[J]. Ann Surg, 2021, 274(1): 120-127.
doi: 10.1097/SLA.0000000000003499 |
[13] | 徐泽宽, 李铮, 徐皓. 从2023年国际胃癌大会看胃癌外科治疗进展与发展趋势[J]. 中国实用外科杂志, 2023, 43(9): 971-974. |
XU Z K, LI Z, XU H. Progress and trends of surgical treatment for gastric cancer from the International Gastric Cancer Congress 2023(IGCC 2023)[J]. Chin J Pract Surg, 2023, 43(9): 971-974. | |
[14] | KITANO S, ISO Y, MORIYAMA M, et al. Laparoscopy-assisted billroth Ⅰ gastrectomy[J]. Surg Laparosc Endosc, 1994, 4(2): 146-148. |
[15] | YOUNG K, MO H, LEE H H, et al. Laproscopic surgery for gastric cancer[M]//Management of Gastric Cancer. InTech, 2011. |
[16] |
KIM H H, HAN S U, KIM M C, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage Ⅰ gastric cancer: the KLASS-01 randomized clinical trial[J]. JAMA Oncol, 2019, 5(4): 506-513.
doi: 10.1001/jamaoncol.2018.6727 |
[17] | KATAI H, MIZUSAWA J, KATAYAMA H, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(2): 142-151. |
[18] |
YU J, HUANG C M, SUN Y H, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial[J]. JAMA, 2019, 321(20): 1983-1992.
doi: 10.1001/jama.2019.5359 |
[19] |
HYUNG W J, YANG H K, HAN S U, et al. A feasibility study of laparoscopic total gastrectomy for clinical stage Ⅰ gastric cancer: a prospective multi-center phase Ⅱ clinical trial, KLASS 03[J]. Gastric Cancer, 2019, 22(1): 214-222.
doi: 10.1007/s10120-018-0864-4 |
[20] |
KATAI H, MIZUSAWA J, KATAYAMA H, et al. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰ gastric cancer: Japan Clinical Oncology Group study JCOG1401[J]. Gastric Cancer, 2019, 22(5): 999-1008.
doi: 10.1007/s10120-019-00929-9 |
[21] |
LIU F L, HUANG C M, XU Z K, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: the CLASS02 multicenter randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1590-1597.
doi: 10.1001/jamaoncol.2020.3152 |
[22] | HASHIZUME M, KONISHI K, TSUTSUMI N, et al. A new era of robotic surgery assisted by a computer-enhanced surgical system[J]. Surgery, 2002, 131(1 Suppl): S330-S333. |
[23] | LI Z Y, ZHOU Y B, LI T Y, et al. Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a multicenter cohort study of 5 402 patients in China[J]. Ann Surg, 2023, 277(1): e87-e95. |
[24] |
OJIMA T, NAKAMURA M, HAYATA K, et al. Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2021, 156(10): 954-963.
doi: 10.1001/jamasurg.2021.3182 |
[25] | ZONG L, ABE M, SETO Y, et al. The challenge of screening for early gastric cancer in China[J]. Lancet, 2016, 388(10060): 2606. |
[26] |
中国胃肠肿瘤外科联盟. 中国胃肠肿瘤外科联盟数据报告(2014—2016)[J]. 中国实用外科杂志, 2018, 38(1): 90-93.
doi: 10.19538/j.cjps.issn1005-2208.2018.01.20 |
China Gastrointestinal Cancer Surgery Union. Data report of China Gastrointestinal Cancer Surgery Union (2014-2016)[J]. Chin J Pract Surg, 2018, 38(1): 90-93. | |
[27] |
SASAKO M, SANO T, YAMAMOTO S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial[J]. Lancet Oncol, 2006, 7(8): 644-651.
doi: 10.1016/S1470-2045(06)70766-5 pmid: 16887481 |
[28] |
SANO T, SASAKO M, MIZUSAWA J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma[J]. Ann Surg, 2017, 265(2): 277-283.
doi: 10.1097/SLA.0000000000001814 pmid: 27280511 |
[29] | KUROKAWA Y, DOKI Y, MIZUSAWA J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(7): 460-468. |
[30] |
SAKURAMOTO S, SASAKO M, YAMAGUCHI T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med, 2007, 357(18): 1810-1820.
doi: 10.1056/NEJMoa072252 |
[31] |
BANG Y J, KIM Y W, YANG H K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315-321.
doi: 10.1016/S0140-6736(11)61873-4 |
[32] |
CUNNINGHAM D, ALLUM W H, STENNING S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20.
doi: 10.1056/NEJMoa055531 |
[33] |
AL-BATRAN S E, HOMANN N, PAULIGK C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957.
doi: 10.1016/S0140-6736(18)32557-1 |
[34] |
ZHANG X T, LIANG H, LI Z Y, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8): 1081-1092.
doi: 10.1016/S1470-2045(21)00297-7 |
[35] |
KANG Y K, YOOK J H, PARK Y K, et al. PRODIGY: a phase Ⅲ study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer[J]. J Clin Oncol, 2021, 39(26): 2903-2913.
doi: 10.1200/JCO.20.02914 |
[36] |
BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697.
doi: 10.1016/S0140-6736(10)61121-X |
[37] |
SHAH M A, SHITARA K, AJANI J A, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial[J]. Nat Med, 2023, 29(8): 2133-2141.
doi: 10.1038/s41591-023-02465-7 pmid: 37524953 |
[38] |
HOFHEINZ R D, HEGEWISCH-BECKER S, KUNZMANN V, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase Ⅱ trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group[J]. Int J Cancer, 2021, 149(6): 1322-1331.
doi: 10.1002/ijc.v149.6 |
[39] |
RIVERA F, IZQUIERDO-MANUEL M, GARCÍA-ALFONSO P, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase Ⅱ trial[J]. Eur J Cancer, 2021, 145: 158-167.
doi: 10.1016/j.ejca.2020.12.005 |
[40] |
JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40.
doi: 10.1016/S0140-6736(21)00797-2 pmid: 34102137 |
[41] |
SHITARA K, VAN CUTSEM E, BANG Y J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580.
doi: 10.1001/jamaoncol.2020.3370 |
[42] | SHITARA K, MOEHLER M H, AJANI J A, et al. Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649[C]. Chicago: ASCO, 2024. |
[43] |
XU J M, JIANG H P, PAN Y Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial[J]. JAMA, 2023, 330(21): 2064-2074.
doi: 10.1001/jama.2023.19918 pmid: 38051328 |
[44] | TERASHIMA M, KANG Y K, KIM Y W, et al. ATTRACTION-5: a phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage Ⅲ (pStage Ⅲ) gastric or gastroesophageal junction (G/GEJ) cancer[J]. J Clin Oncol, 2023, 41(16_suppl): 4000. |
[45] |
SHITARA K, RHA S Y, WYRWICZ L S, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study[J]. Lancet Oncol, 2024, 25(2): 212-224.
doi: 10.1016/S1470-2045(23)00541-7 pmid: 38134948 |
[46] | JANJIGIAN Y Y, AL-BATRAN S E, WAINBERG Z A, et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study[J]. J Clin Oncol, 2024, 42(3_suppl): LBA246. |
[47] |
JANJIGIAN Y Y, KAWAZOE A, BAI Y X, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]. Lancet, 2023, 402(10418): 2197-2208.
doi: 10.1016/S0140-6736(23)02033-0 pmid: 37871604 |
[48] |
AL-BATRAN S E, HOMANN N, PAULIGK C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial[J]. JAMA Oncol, 2017, 3(9): 1237-1244.
doi: 10.1001/jamaoncol.2017.0515 |
[49] |
LUO H Y, XU G L, LI C F, et al. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study[J]. Lancet Oncol, 2019, 20(12): 1645-1654.
doi: S1470-2045(19)30637-0 pmid: 31591062 |
[50] |
DONG D, FANG M J, TANG L, et al. Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study[J]. Ann Oncol, 2020, 31(7): 912-920.
doi: S0923-7534(20)39294-2 pmid: 32304748 |
[51] |
DONG D, TANG L, LI Z Y, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer[J]. Ann Oncol, 2019, 30(3): 431-438.
doi: S0923-7534(19)31081-6 pmid: 30689702 |
[52] |
SUNDAR R, BARR KUMARAKULASINGHE N, HUAK CHAN Y, et al. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase Ⅲ SAMIT trial[J]. Gut, 2022, 71(4): 676-685.
doi: 10.1136/gutjnl-2021-324060 |
[53] |
KATHER J N, PEARSON A T, HALAMA N, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer[J]. Nat Med, 2019, 25(7): 1054-1056.
doi: 10.1038/s41591-019-0462-y pmid: 31160815 |
[54] |
CHEN Q Y, XIE J W, ZHONG Q, et al. Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2020, 155(4): 300-311.
doi: 10.1001/jamasurg.2019.6033 |
[55] | CHEN Q Y, ZHONG Q, LIU Z Y, et al. Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: long-term outcomes of a phase 3 randomised clinical trial[J]. Nat Commun, 2023, 14(1): 7413. |
[1] | 刘帅, 张凯, 张晓青, 栾巍. 派安普利单抗联合安罗替尼和化疗围手术期治疗局部进展期胃癌的探索性研究[J]. 中国癌症杂志, 2024, 34(7): 659-668. |
[2] | 汪斐, 刘佩, 胡楠. 贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响研究[J]. 中国癌症杂志, 2024, 34(5): 493-500. |
[3] | 上海市抗癌协会胃癌专业委员会, 中国人体健康科技促进会胃肠肿瘤专业委员会. 侵犯邻近脏器的进展期胃癌的临床诊疗中国专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(5): 517-526. |
[4] | 钱斌, 陈海泉. 2023年度肺癌外科治疗领域重要进展[J]. 中国癌症杂志, 2024, 34(4): 335-339. |
[5] | 冯征, 郭勤浩, 朱俊, 吴小华, 温灏. 2023年度妇科恶性肿瘤治疗进展及展望[J]. 中国癌症杂志, 2024, 34(4): 340-360. |
[6] | 许永虎, 徐大志. 21世纪以来胃癌治疗进展及未来展望[J]. 中国癌症杂志, 2024, 34(3): 239-249. |
[7] | 薛驰, 高鹏, 朱志, 王振宁. 免疫治疗在胃癌的围手术期及转化治疗中的应用和挑战[J]. 中国癌症杂志, 2024, 34(3): 259-267. |
[8] | 沈洁, 王江立, 王泽洲, 莫淼, 周昌明, 袁晶, 徐大志, 郑莹. 以大型单中心医院登记为基础的6 737例接受手术切除的胃癌患者的生存报告[J]. 中国癌症杂志, 2024, 34(3): 268-277. |
[9] | 李晶, 郑磊, 高钰. 曲妥珠单抗辅助改良DOF双周方案对顺铂耐药的胃癌患者血清肿瘤标志物及生存率的影响分析[J]. 中国癌症杂志, 2024, 34(3): 286-292. |
[10] | 张琪, 修秉虬, 吴炅. 2023年中国乳腺癌重要临床研究成果及最新进展[J]. 中国癌症杂志, 2024, 34(2): 135-142. |
[11] | 张思源, 江泽飞. 2023年改变晚期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 143-150. |
[12] | 刘志昱, 徐栋, 陈西昊, 李纪鹏. 局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建[J]. 中国癌症杂志, 2024, 34(2): 191-200. |
[13] | 冯惠枝, 柳婧美, 卜晓倩. 帕博利珠单抗联合XELOX方案治疗晚期胃癌的回顾性研究[J]. 中国癌症杂志, 2024, 34(11): 1028-1035. |
[14] | 李桐, 杨慧娟. 卵巢黏液性癌的诊治进展[J]. 中国癌症杂志, 2024, 34(1): 90-96. |
[15] | 孙洋, 王炼, 赵萌, 张小凤, 耿志军, 王月月, 宋雪, 左芦根, 李静, 胡建国. 胃癌中FKBP1A高表达的预后价值及其靶向PI3K/AKT对糖代谢的调控作用[J]. 中国癌症杂志, 2023, 33(8): 726-739. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||
地址:上海市徐汇区东安路270号复旦大学附属肿瘤医院10号楼415室
邮编:200032 电话:021-64188274 E-mail:zgazzz@china-oncology.com
访问总数:; 今日访问总数:; 当前在线人数:
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn